POEMs & Tips

From Other Journals

Imiquimod Cream Is Effective for Basal Cell Carcinoma

Am Fam Physician. 2004 Sep 1;70(5):932.

Clinical Question: Is imiquimod cream (an immune response modifier) effective in the treatment of basal cell carcinoma?

Setting: Outpatient (specialty)

Study Design: Randomized controlled trial (double-blinded)

Synopsis: The authors summarized the results of two similar randomized double-blind trials (concealed allocation assignment) comparing imiquimod 5 percent cream applied once daily five and seven times per week for six weeks with an identical, vehicle-only cream. Lesions were confirmed through biopsy to be superficial basal cell carcinomas (i.e., no evidence of aggressive growth patterns) at baseline and were located on the limbs, trunk, neck, or head (excluding the facial H-zone). The maximal lesion diameter was 2 cm. Following treatment, excisions were performed with a 3 to 4 mm margin around the original lesion to determine if the basal cell carcinoma was evident clinically. Outcomes were assessed by persons blinded to treatment group assignment.

A total of 694 patients (96 percent of the initial cohort) were available for follow-up at 12 weeks. Using intention-to-treat analysis, the combined clinical and histologic assessment of tumor clearance for the groups treated five and seven times per week was 75 percent and 73 percent, respectively, compared with 2 to 3 percent in the vehicle-only group (P < .001; number needed to treat = 1.4). In the imiquimod group, 11 patients (3 percent) discontinued treatment because of adverse effects. The most common side effects included skin erythema, erosion, and scabbing/crusting.

Bottom Line: Imiquimod 5 percent cream is an effective and relatively safe nonsurgical alternative for the treatment of superficial basal cell carcinoma. (Level of Evidence: 1b)

Copyright © 2004 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.